Skip to main content
Top
Published in: Journal of Diabetes & Metabolic Disorders 1/2019

01-06-2019 | Hyperglycemia | Research article

Impact of alexithymia on glycemic control among Lebanese adults with type 2 diabetes

Authors: Chirine Fares, Robert Bader, José-Noel Ibrahim

Published in: Journal of Diabetes & Metabolic Disorders | Issue 1/2019

Login to get access

Abstract

Purpose

Alexithymia, defined as the inability of a person to identify, describe and express emotions, has been found to influence glycemic control in type 2 diabetes patients (D2). The characteristics and influencing factors of alexithymia and the association of this psychological construct with D2 has not yet been studied in Lebanon where 14.6% of adults are diagnosed with the disease. This study aims at evaluating the prevalence of alexithymia and its relationship with glycemic control among Lebanese adults with D2.

Methods

Alexithymia was assessed in 104 patients diagnosed with D2 and 100 healthy controls using the 20-item Toronto Alexithymia Scale (TAS-20). The impact of alexithymia on glycemic control was evaluated using HbA1c values, fasting blood glucose levels, number of severe hyperglycemic episodes and hospitalizations for hyperglycemia within the past months.

Results

Alexithymia prevalence was significantly higher in D2 patients compared to controls (35.5% vs 15%). Patients with alexithymia showed higher levels of HbA1c and glucose in comparison to those without alexithymia. Consistently, significant positive correlations were found between the TAS-20 total and subscale scores and both HbA1c and glucose levels. Alexithymic patients had three times more severe hyperglycemic episodes and five times more hospitalizations for hyperglycemia compared to those without alexithymia. According to multivariate regression analysis, lifestyle factors alone were not found predictive of alexithymia in D2 patients.

Conclusion

Given the impact of alexithymia on D2 regulation, screening of alexithymia in case of D2 and appropriate psychological follow-up are important for a better prognosis, management and treatment of the disease.
Literature
4.
go back to reference Chen L, Pei J-H, Kuang J, Chen H-M, Chen Z, Li Z-W, et al. Effect of lifestyle intervention in patients with type 2 diabetes: a meta-analysis. Metabolism. 2015;64:338–47.CrossRefPubMed Chen L, Pei J-H, Kuang J, Chen H-M, Chen Z, Li Z-W, et al. Effect of lifestyle intervention in patients with type 2 diabetes: a meta-analysis. Metabolism. 2015;64:338–47.CrossRefPubMed
5.
go back to reference Whitworth SR, Bruce DG, Starkstein SE, Davis WA, Davis TME, Bucks RS. Lifetime depression and anxiety increase prevalent psychological symptoms and worsen glycemic control in type 2 diabetes: the Fremantle diabetes study phase II. Diabetes Res Clin Pract. 2016;122:190–7.CrossRefPubMed Whitworth SR, Bruce DG, Starkstein SE, Davis WA, Davis TME, Bucks RS. Lifetime depression and anxiety increase prevalent psychological symptoms and worsen glycemic control in type 2 diabetes: the Fremantle diabetes study phase II. Diabetes Res Clin Pract. 2016;122:190–7.CrossRefPubMed
6.
go back to reference Luca A, Luca M, Di Mauro M, Palermo F, Rampulla F, Calandra C. Alexithymia, more than depression, influences glycaemic control of type 2 diabetic patients. J Endocrinol Investig. 2015;38:653–60.CrossRef Luca A, Luca M, Di Mauro M, Palermo F, Rampulla F, Calandra C. Alexithymia, more than depression, influences glycaemic control of type 2 diabetic patients. J Endocrinol Investig. 2015;38:653–60.CrossRef
7.
go back to reference Topsever P, Filiz TM, Salman S, Sengul A, Sarac E, Topalli R, et al. Alexithymia in diabetes mellitus. Scott Med J. 2006;51:15–20.CrossRefPubMed Topsever P, Filiz TM, Salman S, Sengul A, Sarac E, Topalli R, et al. Alexithymia in diabetes mellitus. Scott Med J. 2006;51:15–20.CrossRefPubMed
8.
go back to reference Bastin P, Luminet O, Buysschaert M, Luts A. Contrôle du diabète et alexithymie : le rôle de l’identification et de la verbalisation des émotions. Louvain Méd. 2004;123:252. Bastin P, Luminet O, Buysschaert M, Luts A. Contrôle du diabète et alexithymie : le rôle de l’identification et de la verbalisation des émotions. Louvain Méd. 2004;123:252.
9.
go back to reference Ahmadieh H, Itani H, Itani S, Sidani K, Kassem M, Farhat K, et al. Diabetes and depression in Lebanon and association with glycemic control: a cross-sectional study. Diabetes Metab Syndr Obes Targets Ther. 2018;11:717–28.CrossRef Ahmadieh H, Itani H, Itani S, Sidani K, Kassem M, Farhat K, et al. Diabetes and depression in Lebanon and association with glycemic control: a cross-sectional study. Diabetes Metab Syndr Obes Targets Ther. 2018;11:717–28.CrossRef
10.
go back to reference Care CTF on PH. Recommendations on screening for type 2 diabetes in adults. CMAJ. 2012;184:1687–96.CrossRef Care CTF on PH. Recommendations on screening for type 2 diabetes in adults. CMAJ. 2012;184:1687–96.CrossRef
11.
go back to reference Bagby RM, Parker JDA, Taylor GJ. The twenty-item Toronto alexithymia scale—I. Item selection and cross-validation of the factor structure. J Psychosom Res. 1994;38:23–32.CrossRefPubMed Bagby RM, Parker JDA, Taylor GJ. The twenty-item Toronto alexithymia scale—I. Item selection and cross-validation of the factor structure. J Psychosom Res. 1994;38:23–32.CrossRefPubMed
12.
go back to reference Parker JDA, Taylor GJ, Bagby RM. The 20-item Toronto alexithymia scale. III. Reliability and factorial validity in a community population. J Psychosom Res. 2003;55:269–75.CrossRefPubMed Parker JDA, Taylor GJ, Bagby RM. The 20-item Toronto alexithymia scale. III. Reliability and factorial validity in a community population. J Psychosom Res. 2003;55:269–75.CrossRefPubMed
13.
go back to reference Loas G, Parker JDA, Otmani O, Verrier A, Fremaux D. Confirmatory factor analysis of the French translation of the 20-item Toronto alexithymia scale. Percept Mot Skills. 1997;85:1018.CrossRefPubMed Loas G, Parker JDA, Otmani O, Verrier A, Fremaux D. Confirmatory factor analysis of the French translation of the 20-item Toronto alexithymia scale. Percept Mot Skills. 1997;85:1018.CrossRefPubMed
14.
go back to reference Bondar RJ, Mead DC. Evaluation of glucose-6-phosphate dehydrogenase from Leuconostoc mesenteroides in the hexokinase method for determining glucose in serum. Clin Chem. 1974;20:586–90.PubMed Bondar RJ, Mead DC. Evaluation of glucose-6-phosphate dehydrogenase from Leuconostoc mesenteroides in the hexokinase method for determining glucose in serum. Clin Chem. 1974;20:586–90.PubMed
15.
go back to reference American Diabetes Association. Standards of medical Care in Diabetes—2015 abridged for primary care providers. Clin Diabetes Publ Am Diabetes Assoc. 2015;33:97–111. American Diabetes Association. Standards of medical Care in Diabetes—2015 abridged for primary care providers. Clin Diabetes Publ Am Diabetes Assoc. 2015;33:97–111.
16.
go back to reference Avci D, Kelleci M. Alexithymia in patients with type 2 diabetes mellitus: the role of anxiety, depression, and glycemic control. Patient Prefer Adherence. 2016;10:1271–7.CrossRefPubMedPubMedCentral Avci D, Kelleci M. Alexithymia in patients with type 2 diabetes mellitus: the role of anxiety, depression, and glycemic control. Patient Prefer Adherence. 2016;10:1271–7.CrossRefPubMedPubMedCentral
17.
go back to reference Damak R, Mnif L, Masmoudi J, Halwani N, Mnif F, Baati I, et al. P02-299 - alexithymia in diabetes type2. Eur Psychiatry. 2010;25:1008.CrossRef Damak R, Mnif L, Masmoudi J, Halwani N, Mnif F, Baati I, et al. P02-299 - alexithymia in diabetes type2. Eur Psychiatry. 2010;25:1008.CrossRef
18.
go back to reference Mnif L, Damak R, Mnif F, Ouanes S, Abid M, Jaoua A, et al. Alexithymia impact on type 1 and type 2 diabetes: a case-control study. Ann Endocrinol. 2014;75:2013–9.CrossRef Mnif L, Damak R, Mnif F, Ouanes S, Abid M, Jaoua A, et al. Alexithymia impact on type 1 and type 2 diabetes: a case-control study. Ann Endocrinol. 2014;75:2013–9.CrossRef
20.
go back to reference Salminen JK, Saarijärvi S, Aärelä E, Toikka T, Kauhanen J. Prevalence of alexithymia and its association with sociodemographic variables in the general population of Finland. J Psychosom Res. 1999;46:75–82.CrossRefPubMed Salminen JK, Saarijärvi S, Aärelä E, Toikka T, Kauhanen J. Prevalence of alexithymia and its association with sociodemographic variables in the general population of Finland. J Psychosom Res. 1999;46:75–82.CrossRefPubMed
21.
go back to reference Stingl M, Naundorf K, vom Felde L, Bernd H. Alexithymia in type I and type II diabetes. Interv Obes Diabetes. 2018;1:1–4. Stingl M, Naundorf K, vom Felde L, Bernd H. Alexithymia in type I and type II diabetes. Interv Obes Diabetes. 2018;1:1–4.
22.
go back to reference Levant RF, Hall RJ, Williams CM, Hasan NT. Gender differences in alexithymia. Psychol Men Masculinity. 2009;10:190–203.CrossRef Levant RF, Hall RJ, Williams CM, Hasan NT. Gender differences in alexithymia. Psychol Men Masculinity. 2009;10:190–203.CrossRef
23.
go back to reference Abramson L, McClelland DC, Brown D, Kelner S. Alexithymic characteristics and metabolic control in diabetic and healthy adults. J Nerv Ment Dis. 1991;179:490–4.CrossRefPubMed Abramson L, McClelland DC, Brown D, Kelner S. Alexithymic characteristics and metabolic control in diabetic and healthy adults. J Nerv Ment Dis. 1991;179:490–4.CrossRefPubMed
24.
go back to reference Contreras CM, Gutiérrez-García AG. Cognitive impairment in diabetes and poor glucose utilization in the intracellular neural milieu. Med Hypotheses. 2017;104:160–5.CrossRefPubMed Contreras CM, Gutiérrez-García AG. Cognitive impairment in diabetes and poor glucose utilization in the intracellular neural milieu. Med Hypotheses. 2017;104:160–5.CrossRefPubMed
26.
go back to reference Morie KP, Yip SW, Nich C, Hunkele K, Carroll KM, Potenza MN. Alexithymia and addiction: a review and preliminary data suggesting neurobiological links to reward/loss processing. Curr Addict Rep. 2016;3:239–48.CrossRefPubMedPubMedCentral Morie KP, Yip SW, Nich C, Hunkele K, Carroll KM, Potenza MN. Alexithymia and addiction: a review and preliminary data suggesting neurobiological links to reward/loss processing. Curr Addict Rep. 2016;3:239–48.CrossRefPubMedPubMedCentral
27.
go back to reference Misterska E, Glowacki M, Adamczyk K, Glowacki J, Harasymczuk J. A longitudinal study of alexithymia in relation to physical activity in adolescent females with scoliosis subjected to cheneau brace treatment: preliminary report. Spine. 2014;39:E1026–34.CrossRefPubMed Misterska E, Glowacki M, Adamczyk K, Glowacki J, Harasymczuk J. A longitudinal study of alexithymia in relation to physical activity in adolescent females with scoliosis subjected to cheneau brace treatment: preliminary report. Spine. 2014;39:E1026–34.CrossRefPubMed
Metadata
Title
Impact of alexithymia on glycemic control among Lebanese adults with type 2 diabetes
Authors
Chirine Fares
Robert Bader
José-Noel Ibrahim
Publication date
01-06-2019
Publisher
Springer International Publishing
Published in
Journal of Diabetes & Metabolic Disorders / Issue 1/2019
Electronic ISSN: 2251-6581
DOI
https://doi.org/10.1007/s40200-019-00412-3

Other articles of this Issue 1/2019

Journal of Diabetes & Metabolic Disorders 1/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.